[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"elective-surgical-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:elective-surgical-patients":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100649580","exploration-of-appropriate-bis-range-and-propofol-effect-site-concentration-during-total-intravenous-anesthesia-with-concomitant-adjuvants-100649580",false,"NCT07736352","Exploration of Appropriate BIS Range and Propofol Effect-site Concentration During Total Intravenous Anesthesia With Concomitant Adjuvants.","A Prospective, Randomized Study to Determine the Appropriate Bispectral Index Range and Propofol Effect-Site Concentration During Total Intravenous Anesthesia Combined With Midazolam, Dexmedetomidine or Esketamine.","Inclusion Criteria:\n\n* Age 18 to 65 years\n* American Society of Anesthesiologists (ASA) physical status I or II\n* Body Mass Index (BMI) 18 to 30 kg\u002Fm²\n* Scheduled for elective unilateral total knee replacement surgery\n* Willing to participate in the study and signed informed consent form, and able to comply with the intervention and assessment procedures\n\nExclusion Criteria:\n\n* History of neurological disorders\n* Cognitive dysfunction assessed by the Mini-Cog scale\n* History of antipsychotic or sedative medication use in the past 4 weeks\n* Poorly controlled or untreated hypertension\n* Sinus bradycardia, cardiac conduction block, or severe heart failure\n* Acute angle-closure glaucoma\n* Allergic to intravenous anesthetics\n* Hearing impairment, could not cooperate in intervention and evaluation\n* Contraindications to tourniquet use on the upper arm","ALL","18 Years","65 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to determine the appropriate Bispectral Index (BIS) range and propofol effect-site concentration required to maintain adequate anesthesia depth during total intravenous anesthesia (TIVA) combined with midazolam, dexmedetomidine, or esketamine in patients undergoing unilateral knee replacement surgery. The main questions it aims to answer are:\n\n1. What are the appropriate BIS range and propofol effect-site concentration for maintaining adequate anesthesia depth when combined with each of the three medications (midazolam, dexmedetomidine, or esketamine) during TIVA?\n2. How these combination regimens affect the quality of recovery and postoperative pain in patients？\n\nParticipants will:\n\n1. Receive one of four anesthesia regimens during surgery: propofol alone, propofol combined with midazolam, dexmedetomidine, or esketamine.\n2. Undergo a stepwise reduction of propofol effect-site concentration towards the end of surgery.\n3. Have their consciousness assessed using the isolated forearm technique, while BIS, EEG signals, and vital signs are continuously monitored throughout the procedure.\n4. Have their recovery quality and postoperative pain assessed after surgery.",[27,28,29,30],"Knee Osteoarthritis","Replacement, Knee","Elective Surgical Patients","ASA Class I\u002FII Patients","NOT_YET_RECRUITING","2026-07-26",{"date":34,"type":35},"2026-07-30","ACTUAL",{"date":37,"type":21},"2026-08-01",{"date":39,"type":21},"2027-07-31",{"name":41,"class":42},"China-Japan Friendship Hospital","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100570273","phase-1-gabapentin-and-pressor-response-to-intubation-100570273","NCT06705101","Gabapentin and Pressor Response to Intubation","GABAPENTIN ATTENUATES THE PRESSOR RESPONSE TO DIRECT LARYNGOSCOPY AND TRACHEAL INTUBATION","Inclusion Criteria:\n\n* ASA I or II patients (American Society of Anesthesiologists Physical Status Classification).\n* Age between 18 and 59 years.\n* Scheduled for elective surgery under general anesthesia with endotracheal intubation.\n\nExclusion Criteria:\n\n* Anticipated difficult intubation.\n* ASA III or greater.\n* Patients with hiatus hernia or gastro-esophageal reflux disease (GERD).\n* Body weight more than 20% of ideal body weight.\n* Patients on antihypertensive drugs, sedatives, hypnotics, or antidepressants.","59 Years",{"count":52,"type":21},144,[54,55],"PHASE1","PHASE2","This study evaluates the effectiveness of oral gabapentin in reducing the pressor response (increased MAP, HR, and BP) during laryngoscopic intubation. It is a prospective, double-blind randomized controlled trial involving 144 patients undergoing elective surgery. Gabapentin 300 mg or placebo will be administered preoperatively, with hemodynamic parameters monitored before and after intubation. The study aims to determine if gabapentin attenuates the sympathetic stress response compared to placebo.",[29,58],"Blood Pressure",[60,61,62,63],"Gabapentin","Laryngoscopy","Hemodynamic Stability","Pressor Response","2024-11-22",{"date":66,"type":35},"2024-11-26",{"date":68,"type":21},"2024-12-15",{"date":70,"type":21},"2025-07-16",{"name":72,"class":42},"Liaquat National Hospital & Medical College"]